Anshu Buttan
Endocrinology, Diabetes & Metabolism · Los Angeles, CANPI 1093158891
Payments from drug & device makers
Across 438 payments — averaging $21.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- Dexcom, Inc.$1K
- Abbott$872
- Amgen$602
- Boehringer Ingelheim$575
- plus $3K from 22 others
What the payments were for
- Food & beverage$9,38899%
- Education$1261%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 109 | $1,978 |
| Lilly USA, LLC | 89 | $1,593 |
| Dexcom, Inc. | 78 | $1,307 |
| Abbott | 60 | $872 |
| Amgen(2 entities) | 11 | $602 |
| Boehringer Ingelheim | 8 | $575 |
| Sanofi-aventis U.S. LLC | 17 | $342 |
| Medtronic(2 entities) | 7 | $308 |
| Inspire Medical Systems, Inc. | 1 | $246 |
| Tandem Diabetes Care, Inc. | 4 | $183 |
| AbbVie(2 entities) | 3 | $175 |
| Xeris Pharmaceuticals, Inc. | 7 | $147 |
| AstraZeneca | 4 | $145 |
| Corcept Therapeutics | 8 | $144 |
| Radius Health, Inc. | 7 | $134 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Bayer | 1 | $96 |
| Mannkind Corporation | 3 | $92 |
| Merck | 5 | $90 |
| Pfizer | 1 | $84 |
| Zealand Pharma US, Inc. | 3 | $55 |
| Currax Pharmaceuticals LLC | 2 | $50 |
| Lifescan, Inc. | 2 | $40 |
| IBSA Pharma Inc. | 2 | $38 |
| BETA Bionics, Inc. | 2 | $35 |
| Johnson & Johnson | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $23 |
| Vistapharm, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$443
- Wegovy$370
- TEPEZZA$250
- Inspire Upper Airway Stimulation System$246
- JARDIANCE$235
- INPEN SMART INSULIN DELIVERY SYSTEM$179
- AVYCAZ$125
- EVENITY$125
- ELIQUIS$121
How this compares
$9,515 in reported general payments places this provider in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 694 | $1,243,098 |
| TrulicityDulaglutide | 162 | $264,423 |
| JardianceEmpagliflozin | 143 | $178,140 |
| FarxigaDapagliflozin Propanediol | 128 | $161,222 |
| MounjaroTirzepatide | 73 | $117,010 |
| TymlosAbaloparatide | 32 | $95,650 |
| ProliaDenosumab | 41 | $70,862 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $47,049 |
| RybelsusSemaglutide | 22 | $36,412 |
| Teriparatide | 19 | $36,174 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $34,144 |
| TradjentaLinagliptin | 28 | $28,391 |
| JanumetSitagliptin Phos/Metformin Hcl | 20 | $25,969 |
| SynjardyEmpagliflozin/Metformin Hcl | 14 | $23,368 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 53 | $21,982 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,978 | $1,279,510716 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,593 | $391,482272 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $575 | $229,900185 claims |
| AstraZenecaFarxiga | $145 | $161,222128 claims |
| Radius Health, Inc.Tymlos | $134 | $95,65032 claims |
| AmgenProlia | $602 | $70,86241 claims |
| MerckJanumet | $90 | $25,96920 claims |
| AbbVieSynthroid | $175 | $5,12656 claims |
| Sanofi-aventis U.S. LLCLantus | $342 | $99313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Los Angeles
- Stanley HsiaLos Angeles$19.8M
- Shlomo MelmedLos Angeles$3.3M
- Sina TebiLos Angeles$2.4M
- Anthony HeaneyLos Angeles$788K
- Christian GastelumLos Angeles$421K
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.